Breakthroughs and Challenges of a New Era in ADPKD Care
$255$395
Over the last three years, the management of patients with Autosomal Dominant Polycystic Kidney Disease (ADPKD) has fundamentally transformed through various advances. Diagnosis is often aided by low-cost next-generation sequencing platforms, and robust risk-stratification strategies identify high-risk patients who may benefit from recently approved treatments. Differences are emerging between ADPKD-specific supportive care and general CKD management. Translating these breakthroughs to clinical practice can be complicated.
This program efficiently addresses these breakthroughs and their accompanying challenges: the diagnostic and risk assessment tools, Food and Drug Administration (FDA) approvals, health disparities, and patient concerns.
